Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034186 (pyelonephritis)
 6,144 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since 1973 30 patients with urinary tract infections (UTI) or pyelonephritis have been treated with sisomicin, a new aminoglycoside, in a daily dose of 2 mg/kg for a period of seven to nine days. From a clinical point of view the result of treatment was good. Complete resolution was achieved in 17 patients, improvement in nine, and there was no effect in four patients. Thirty-five causative organisms (Escherichia coli = 23, Proteus sp. = 7, Klebsiella sp. = 3, Pseudomonas aeruginosa = 1, Citrobacter = 1) were isolated before treatment. Thirty of the organisms were eliminated during treatment, but seven reappeared during the follow-up period; five strains persisted. Side effects observed consisted of reversible increase of serum creatinine in four patients, excretion of granular casts in 14 patients, and a transient rise of alkaline phosphatase, SGOT and/or SGPT in five patients. No signs of ototoxicity or any other adverse reactions were found and local tolerance was good. In 20 patients blood samples for assay were obtained daily one hour after i. m. injection of 1.0 mg/kg. No evidence of drug accumulation in the serum was found: the mean serum concentrations one hour after injection remained between 3.4 and 3,9 microgram/ml during the entire treatment period. Sisomicin is a highly effective antibiotic for the treatment of UTI caused by gramnegative pathogens. On account of its potential toxicity however, it should be used, like other aminoglycosides, only in selected cases.
Infection 1978
PMID:[Efficacy, tolerance, and pharmacokinetics of sisomicin in urinary tract infections (author's transl)]. 10 44

The role of urease in induction of pyelonephritis was studied by treatment of proteus-infected rats with acetohydroxamic acid, a potent inhibitor of urease. Infection was produced by introduction of Proteus mirabilis into the bladder along with a zinc disk. Controls were treated identically but received no acetohydroxamic acid. The number of bacteria per milliliter of urine was the same in both groups. The number of bacteria in the kidneys and the extent of renal damage was much greater in controls. Common enterobacteraceal antigen was not detected in the renal parenchyma of rats treated with acetohydroxamic acid. Treatment with acetohydroxamic acid thus prevented invasion of and damage to kidney tissue without reduction of urinary infection. Thus new evidence was found that the invasive properties of Proteus in the urinary tract are dependent on alkalinization of urine by urease and the resulting damage to the renal epithelium.
 ...
PMID:Role of urease in pyelonephritis resulting from urinary tract infection with Proteus. 23 93

The clinical efficacy and toleration of amikacin was investigated in 22 patients most of whom had chronic urinary tract infections that had already been treated unsuccessfully on several occasions with other antibiotics. Amikacin was administered i.m. in a dosage of 7.5 mg per kg twice daily for an average of 11.4 days. This new aminoglycoside antibiotic proved highly effective in the treatment of chronic pyelonephritis and cystitis, as well as in septicaemia caused by gentamicin-resistant Pseudomonas. The pharmacokinetic studies did not show any retention after a ten day treatment with amikacin. Thorough nephrologic and otologic investigations for side-effects did not show any permanent nephrotoxic or ototoxic damage or delayed damage. The results were compared with the clinical and experimental data in the literature and with the results of experimental studies which have not yet been published.
Infection 1979
PMID:[Clinical efficacy, nephrotoxicity and ototoxicity of amikacin]. 37 77

In a long-term investigation in children and adult patients with urinary tract infection, 1403 Escherichia coli strains were serotyped and 266 strains were subjected to serological investigation. The most frequently occurring O groups were O6, O8, O2, O18, O4, O75, O1, O22, O7 and O9. L type antigens were predominant among the K antigens. Infants in whom pyelonephritis manifested itself for the first time exhibited an above average rate of infection with O2, O4 and O75. A reinfection rate of 84 to 91% was observed in children in follow-up investigations.
Infection 1979
PMID:[Typing of Escherichia coli O and K antigens in patients with urinary tract infections (author's transl)]. 37 79

Sisomicin, an aminoglycoside antibiotic, is especially effective against Escherichia coli, Klebsiella, Enterobacter, Citrobacter, Serratia, indole-positive and indole-negative Proteus species, Pseudomonas aeruginosa, Salmonella and Staphylococcus aureus. It has a bactericidal action. Although sisomicin is similar to the other aminoglycoside antibiotics, there is not complete cross-resistance to them. Our own pharmacokinetic investigations showed that a dose of 2--3 mg/kg body weight of sisomicin twice daily is necessary in the neonatal period. Infants should be given 2.5 mg/kg body weight three times daily, and school children 1.5--20 mg/kg body weight, likewise three times daily. Excretion of sisomicin in the urine is lower in children than in adults, amounting within 24 hours to only 10--20% in newborns, and 30--40% in school-children. Sisomicin induces excretion of some enzymes in higher quantities from the tubular part of the kidneys, especially alaninaminopeptidase. A report is given on 58 patients, especially newborns and prematures, who were treated for about seven days with sisomicin. The results obtained with a wide variety of infections (such as omphalitis, aspiration of amniotic fluid with broncho-pneumonia, phlegmons of the galea, and also pyelonephritis and mucoviscidosis with pulmonary complications) can be described as good, with a success rate of 85%. On only seven occasions were insignificant transitory side-effects, such as slight increase in transaminases, toxic-allergic exanthema and pain in the region in injection, observed.
Infection 1979
PMID:[Experience with sisomicin in pediatrics (author's transl)]. 38 23

Co-trimazine, a new combination of trimethoprim and sulphadiazine intended for treatment of urinary tract infections, was tested and compared to co-trimoxazole in an experimental model of acute, obstructive pyelonephritis in the rat. The tests were carried out at four dose levels corresponding to the clinically recommended doses and to 1/4, 1/2, and 3/4 of the latter. The drugs were administered orally. Co-trimazine was found to have a greater antibacterial activity than co-trimoxazole and its use at a lower dosage than that of the latter appears warranted.
Infection 1979
PMID:Efficacy of two trimethoprim-sulphonamide combinations in experimental pyelonephritis in the rat. 38 11

Bacampicillin and ampicillin were tested and compared with each other in a model of acute, obstructive pyelonephritis in the rat. The compounds were administered orally at five dose levels ranging from 50 mg/kg to 150 mg/kg. Bacampicillin was found to have a greater therapeutic activity than ampicillin, particulary at the higher doses, indicating that its improved absorption properties make it a therapeutically more effective compound than ampicillin.
Infection 1979
PMID:Efficacy of bacampicillin and ampicillin in experimental pyelonephritis in the rat. 38 22

A comparative study on the antibiotic activity of cefaclor and cephradine was performed in an infection and therapy model of acute pyelonephritis in the rat. Pathogens were Escherichia coli and Klebsiella pneumoniae. The antibiotics, which were administered orally, both had a pronounced effect in comparison to the untreated control group. Cefaclor was superior to cephradine in infections caused by K. pneumoniae.
Infection 1979
PMID:[Influence of cefaclor on experimental pyelonephritis (author's transl)]. 39 49

The clinical symptoms of urinary tract infections (UTI) are only rarely an indication of the presence of the disease in childhood. Of decisive importance for the detection of UTI is an appropriate investigation to determine whether there is significant bacteriuria. Since in a significant proportion of cases of UTI in children there is underlying congenital anomaly or functional change in the urinary tract with stasis, and since surgical means of treatment are available today, diagnosis, i.e. at least radiological exploration, is essential. Approximately half the children with UTI are younger than one year at the time of diagnosis. In neonates, boys are more frequently affected than girls, whereas in older age-groups the incidence of significant bacteriuria (approximately 1.5%) and clinically relevant UTI or pyelonephritis is higher in females than in males. "Idiopathic" ("non-urologically induced") UTI is very seldom found in boys after infancy, and "asymptomatic bacteriuria" is largely confined to females. The "urethral syndrome" is probably caused by minor obstruction of the urethra and "bladder-sphincter dyssynergy". The fact that approximately nine of ten cases of UTI relapse in children are due to reinfection with a different pathogen has certain consequences for therapy. Prophylactic long-term medication is recommended during the phase after surgical correction of anomalies of the urinary tract.
Infection 1979
PMID:[Urinary tract infections in childhood (author's transl)]. 55 Oct 80

The frequency of chronic pyelonephritis is often overestimated. Chronic pyelonephritis is probably always a secondary disease in cases with obstructive changes in the ureters or other primary renal damage. The influence of chronic infection on the progression of renal insufficiency is still not well understood today. Underlying disease and infection should always be taken into consideration in the treatment of chronic pyelonephritis.
Infection 1979
PMID:[Chronic pyelonephritis in adults (author's transl)]. 55 Oct 81


1 2 3 4 5 6 7 8 9 10 Next >>